Acute venous thromboembolism plasma and red blood cell metabolomic profiling reveals potential new early diagnostic biomarkers: observational clinical study.
Deep vein thrombosis
Metabolomics
Pulmonary embolism
Venous thromboembolism
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
24 Feb 2024
24 Feb 2024
Historique:
received:
28
10
2023
accepted:
10
01
2024
medline:
25
2
2024
pubmed:
25
2
2024
entrez:
24
2
2024
Statut:
epublish
Résumé
Venous thromboembolism (VTE) is a leading cause of cardiovascular mortality. The diagnosis of acute VTE is based on complex imaging exams due to the lack of biomarkers. Recent multi-omics based research has contributed to the development of novel biomarkers in cardiovascular diseases. Our aim was to determine whether patients with acute VTE have differences in the metabolomic profile compared to non-acute VTE. This observational trial included 62 patients with clinical suspicion of acute deep vein thrombosis or pulmonary embolism, admitted to the emergency room. There were 50 patients diagnosed with acute VTE and 12 with non-acute VTE conditions and no significant differences were found between the two groups for clinical and demographic characteristics. Metabolomics assays identified and quantified a final number of 91 metabolites in plasma and 55 metabolites in red blood cells (RBCs). Plasma from acute VTE patients expressed tendency to a specific metabolomic signature, with univariate analyses revealing 23 significantly different molecules between acute VTE patients and controls (p < 0.05). The most relevant metabolic pathway with the strongest impact on the acute VTE phenotype was D-glutamine and D-glutamate (p = 0.001, false discovery rate = 0.06). RBCs revealed a specific metabolomic signature in patients with a confirmed diagnosis of DVT or PE that distinguished them from other acutely diseased patients, represented by 20 significantly higher metabolites and four lower metabolites. Three of those metabolites revealed high performant ROC curves, including adenosine 3',5'-diphosphate (AUC 0.983), glutathione (AUC 0.923), and adenine (AUC 0.91). Overall, the metabolic pathway most impacting to the differences observed in the RBCs was the purine metabolism (p = 0.000354, false discovery rate = 0.68). Our findings show that metabolite differences exist between acute VTE and nonacute VTE patients admitted to the ER in the early phases. Three potential biomarkers obtained from RBCs showed high performance for acute VTE diagnosis. Further studies should investigate accessible laboratory methods for the future daily practice usefulness of these metabolites for the early diagnosis of acute VTE in the ER.
Sections du résumé
BACKGROUND
BACKGROUND
Venous thromboembolism (VTE) is a leading cause of cardiovascular mortality. The diagnosis of acute VTE is based on complex imaging exams due to the lack of biomarkers. Recent multi-omics based research has contributed to the development of novel biomarkers in cardiovascular diseases. Our aim was to determine whether patients with acute VTE have differences in the metabolomic profile compared to non-acute VTE.
METHODS
METHODS
This observational trial included 62 patients with clinical suspicion of acute deep vein thrombosis or pulmonary embolism, admitted to the emergency room. There were 50 patients diagnosed with acute VTE and 12 with non-acute VTE conditions and no significant differences were found between the two groups for clinical and demographic characteristics. Metabolomics assays identified and quantified a final number of 91 metabolites in plasma and 55 metabolites in red blood cells (RBCs). Plasma from acute VTE patients expressed tendency to a specific metabolomic signature, with univariate analyses revealing 23 significantly different molecules between acute VTE patients and controls (p < 0.05). The most relevant metabolic pathway with the strongest impact on the acute VTE phenotype was D-glutamine and D-glutamate (p = 0.001, false discovery rate = 0.06). RBCs revealed a specific metabolomic signature in patients with a confirmed diagnosis of DVT or PE that distinguished them from other acutely diseased patients, represented by 20 significantly higher metabolites and four lower metabolites. Three of those metabolites revealed high performant ROC curves, including adenosine 3',5'-diphosphate (AUC 0.983), glutathione (AUC 0.923), and adenine (AUC 0.91). Overall, the metabolic pathway most impacting to the differences observed in the RBCs was the purine metabolism (p = 0.000354, false discovery rate = 0.68).
CONCLUSIONS
CONCLUSIONS
Our findings show that metabolite differences exist between acute VTE and nonacute VTE patients admitted to the ER in the early phases. Three potential biomarkers obtained from RBCs showed high performance for acute VTE diagnosis. Further studies should investigate accessible laboratory methods for the future daily practice usefulness of these metabolites for the early diagnosis of acute VTE in the ER.
Identifiants
pubmed: 38402378
doi: 10.1186/s12967-024-04883-8
pii: 10.1186/s12967-024-04883-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
200Informations de copyright
© 2024. The Author(s).
Références
Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34:2363–71.
pubmed: 25304324
doi: 10.1161/ATVBAHA.114.304488
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464–74.
pubmed: 26076949
pmcid: 4624298
doi: 10.1038/nrcardio.2015.83
Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Deep vein thrombosis: update on diagnosis and management. Med J Aust. 2019;210:516–24.
pubmed: 31155730
doi: 10.5694/mja2.50201
Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130:1636–61.
pubmed: 25246013
doi: 10.1161/CIR.0000000000000130
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543–603.
pubmed: 31504429
doi: 10.1093/eurheartj/ehz405
Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–738.
pubmed: 33007077
pmcid: 7556153
doi: 10.1182/bloodadvances.2020001830
Roy P-M, Douillet D, Penaloza A. Contemporary management of acute pulmonary embolism. Trends Cardiovasc Med. 2022;32:259–68.
pubmed: 34214598
doi: 10.1016/j.tcm.2021.06.002
Metabolites | Free Full-Text | Metabolomic Profile in Venous Thromboembolism (VTE) [Internet]. [cited 2023 July 6]. Available from: https://www.mdpi.com/2218-1989/11/8/495 .
Wawrzyniak R, Garcia Alvarez A, Rupérez F, Nuño-Ayala M, Garcia A, Ruiz-Cabello J, et al. Metabolomics reveals metabolite changes in acute pulmonary embolism. J Proteome Res. 2013;13:1.
Maekawa K, Sugita C, Yamashita A, Moriguchi-Goto S, Furukoji E, Sakae T, et al. Higher lactate and purine metabolite levels in erythrocyte-rich fresh venous thrombus: potential markers for early deep vein thrombosis. Thromb Res. 2019;177:136–44.
pubmed: 30901608
doi: 10.1016/j.thromres.2019.03.011
Al Za’abi M, Ali BH, ALOthman ZA, Ali I. Analyses of acute kidney injury biomarkers by ultra-high performance liquid chromatography with mass spectrometry. J Sep Sci. 2016;39:69–82.
pubmed: 26420427
doi: 10.1002/jssc.201500982
Gehrke S, Shah N, Gamboni F, Kamyszek R, Srinivasan AJ, Gray A, et al. Metabolic impact of red blood cell exchange with rejuvenated red blood cells in sickle cell patients. Transfusion (Paris). 2019;59:3102–12.
doi: 10.1111/trf.15467
Hernández-Alonso P, Becerra-Tomás N, Papandreou C, Bulló M, Guasch-Ferré M, Toledo E, et al. Plasma metabolomics profiles were associated with the amount and source of protein intake: a metabolomics approach within the PREDIMED study. Mol Nutr Food Res. 2020;64:e2000178.
pubmed: 32378786
pmcid: 9245364
doi: 10.1002/mnfr.202000178
Wehrens R, Hageman JA, van Eeuwijk F, Kooke R, Flood PJ, Wijnker E, et al. Improved batch correction in untargeted MS-based metabolomics. Metabolomics. 2016;12:88.
pubmed: 27073351
pmcid: 4796354
doi: 10.1007/s11306-016-1015-8
Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucl Acids Res. 2009;37:W652–60.
pubmed: 19429898
pmcid: 2703878
doi: 10.1093/nar/gkp356
Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17:1735–61.
pubmed: 35715522
doi: 10.1038/s41596-022-00710-w
Clinical Metabolomic Landscape of Cardiovascular Physiology and Disease [Internet]. [cited 2023 Dec 27]. Available from: https://doi.org/10.1161/JAHA.122.027725 .
Eriksson L, Byrne T, Johansson E, Trygg J, Vikström C. Multi- and Megavariate Data Analysis Basic Principles and Applications. Umetrics Academy; 2013.
Xia J. Computational Strategies for Biological Interpretation of Metabolomics Data. In: Sussulini A, editor. Metabolomics Fundam Clin Appl [Internet]. Cham: Springer International Publishing; 2017 [cited 2023 Dec 27]. p. 191–206. Available from: https://doi.org/10.1007/978-3-319-47656-8_8 .
Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol. 1996;58:267–88.
Human Metabolome Database [Internet]. [cited 2023 Aug 9]. Available from: https://hmdb.ca/ .
Clinical Metabolomic Landscape of Cardiovascular Physiology and Disease [Internet]. [cited 2023 Sep 15]. Available from: https://doi.org/10.1161/JAHA.122.027725 .
Zhao J, Yang S, Jing R, Jin H, Hu Y, Wang J, et al. Plasma metabolomic profiles differentiate patients with dilated cardiomyopathy and ischemic cardiomyopathy. Front Cardiovasc Med. 2020;7:597546.
pubmed: 33240942
pmcid: 7683512
doi: 10.3389/fcvm.2020.597546
Iida M, Harada S, Takebayashi T. Application of metabolomics to epidemiological studies of atherosclerosis and cardiovascular disease. J Atheroscler Thromb. 2019;26:747–57.
pubmed: 31378756
pmcid: 6753246
doi: 10.5551/jat.RV17036
Weisel JW, Litvinov RI. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost JTH. 2019;17:271–82.
pubmed: 30618125
doi: 10.1111/jth.14360
Deguchi H, Banerjee Y, Trauger S, Siuzdak G, Kalisiak E, Fernández JA, et al. Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. Blood. 2015;126:1595–600.
pubmed: 26175037
pmcid: 4582336
doi: 10.1182/blood-2015-03-636761
Jiang X, Zeleznik OA, Lindström S, Lasky-Su J, Hagan K, Clish CB, et al. Metabolites associated with the risk of incident venous thromboembolism: a metabolomic analysis. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2018;7:e010317.
doi: 10.1161/JAHA.118.010317
Li S, Gao D, Jiang Y. Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma. Metabolites [Internet]. 2019 [cited 2023 Sep 21];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410233/ .
Gillespie AH, Doctor A. Red Blood Cell Contribution to Hemostasis. Front Pediatr [Internet]. 2021 [cited 2023 Aug 1];9. Available from: https://doi.org/10.3389/fped.2021.629824
Weisel JW, Litvinov RI. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost. 2019;17:271–82.
pubmed: 30618125
pmcid: 6932746
doi: 10.1111/jth.14360
D’Alessandro A, Anastasiadi AT, Tzounakas VL, Nemkov T, Reisz JA, Kriebardis AG, et al. Red blood cell metabolism in vivo and in vitro. Metabolites. 2023;13:793.
pubmed: 37512500
pmcid: 10386156
doi: 10.3390/metabo13070793
D’Alessandro A, Zolla L. Proteomic analysis of red blood cells and the potential for the clinic: what have we learned so far? Expert Rev Proteomics. 2017;14:243–52.
pubmed: 28162022
doi: 10.1080/14789450.2017.1291347
Lin E-S, Yang Y-S. Colorimetric determination of the purity of 3′-phospho adenosine 5′-phosphosulfate and natural abundance of 3′-phospho adenosine 5′-phosphate at picomole quantities. Anal Biochem. 1998;264:111–7.
pubmed: 9784194
doi: 10.1006/abio.1998.2800
Toledano E, Ogryzko V, Danchin A, Ladant D, Mechold U. 3′–5′ Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo. Biochem J. 2012;443:485–90.
pubmed: 22240080
doi: 10.1042/BJ20111057
Klaassen CD, Boles JW. Sulfation and sulfotransferases 5: the importance of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J Off Publ Fed Am Soc Exp Biol. 1997;11:404–18.
Lindahl U, Kusche-Gullberg M, Kjellén L. Regulated diversity of heparan sulfate *. J Biol Chem. 1998;273:24979–82.
pubmed: 9737951
doi: 10.1074/jbc.273.39.24979
Vogt AM, Winter G, Wahlgren M, Spillmann D. Heparan sulphate identified on human erythrocytes: a plasmodium falciparum receptor. Biochem J. 2004;381:593–7.
pubmed: 15209561
pmcid: 1133867
doi: 10.1042/BJ20040762
Alkhamis TM, Alma’atah BM. Evaluation of red blood cell contribution to platelet activation in the bulk applying red blood cell—platelet thrombus as a point source model. Adv Biosci Biotechnol. 2022;13:92–111.
doi: 10.4236/abb.2022.132004
Heptinstall S, Johnson A, Glenn JR, White AE. Adenine nucleotide metabolism in human blood—important roles for leukocytes and erythrocytes. J Thromb Haemost. 2005;3:2331–9.
pubmed: 16150046
doi: 10.1111/j.1538-7836.2005.01489.x
Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86:222–32.
pubmed: 11487010
doi: 10.1055/s-0037-1616220
Chopra V, Marmur JD, Cavusoglu E. The role of clopidogrel in the management of patients with ischemic heart disease. Cardiovasc Drugs Ther. 2003;17:467–77.
pubmed: 15107602
doi: 10.1023/B:CARD.0000015862.62649.c8
Mikdar M, Serra M, Colin E, Duval R, Gauthier E-F, Lamarre Y, et al. Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation. Haematologica. 2023;2023:1.
Zeleznik OA, Poole EM, Lindstrom S, Kraft P, Van Hylckama VA, Lasky-Su JA, et al. Metabolomic analysis of 92 pulmonary embolism patients from a nested case–control study identifies metabolites associated with adverse clinical outcomes. J Thromb Haemost. 2018;16:500–7.
pubmed: 29285876
pmcid: 5826867
doi: 10.1111/jth.13937
Sung Y, Spagou K, Kafeza M, Kyriakides M, Dharmarajah B, Shalhoub J, et al. Deep vein thrombosis exhibits characteristic serum and vein wall metabolic phenotypes in the inferior vena cava ligation mouse model. Eur J Vasc Endovasc Surg. 2018;55:703–13.
pubmed: 29526653
doi: 10.1016/j.ejvs.2018.01.027
Türker FS, Malbora A, Erisir M. Oxidative status and antioxidant enzyme levels in deep venous thrombosis patients. Am J Cardiovasc Dis. 2021;11:176–83.
pubmed: 33815933
pmcid: 8012287
Aykal G, Güven R, Yeğin A, Ellidağ HY, Bayindir A, Yilmaz N. The diagnostic value of oxidative/antioxidative balance parameters in venous thromboembolism. Clin Lab. 2015;61:769–75.
pubmed: 26299076
doi: 10.7754/Clin.Lab.2015.141106
Poredoš P, Spirkoska A, Ježovnik MK. In patients with superficial vein thrombosis the inflammatory response is increased and related to the recanalization rate. Arch Med Sci AMS. 2019;15:393–401.
pubmed: 30899292
doi: 10.5114/aoms.2019.83292
Clapp BR, Hingorani AD, Kharbanda RK, Mohamed-Ali V, Stephens JW, Vallance P, et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004;64:172–8.
pubmed: 15364625
doi: 10.1016/j.cardiores.2004.06.020
Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005;26:3–4.
pubmed: 15615791
doi: 10.1093/eurheartj/ehi041
Laborde CM, Mourino-Alvarez L, Posada-Ayala M, Alvarez-Llamas G, Serranillos-Reus MG, Moreu J, et al. Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome. Metabolomics. 2014;10:414–24.
pubmed: 25814918
doi: 10.1007/s11306-013-0595-9
Surendran A, Atefi N, Zhang H, Aliani M, Ravandi A. Defining acute coronary syndrome through metabolomics. Metabolites. 2021;11:685.
pubmed: 34677400
pmcid: 8540033
doi: 10.3390/metabo11100685
Liu Y, Li Y, Zhang T, Zhao H, Fan S, Cai X, et al. Analysis of biomarkers and metabolic pathways in patients with unstable angina based on ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Mol Med Rep. 2020;22:3862–72.
pubmed: 32901869
pmcid: 7533448
Fan Y, Li Y, Chen Y, Zhao Y-J, Liu L-W, Li J, et al. Comprehensive metabolomic characterization of coronary artery diseases. J Am Coll Cardiol. 2016;68:1281–93.
pubmed: 27634119
doi: 10.1016/j.jacc.2016.06.044
Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years [Internet]. [cited 2023 Sep 20]. Available from: https://doi.org/10.1161/HYPERTENSIONAHA.119.13643 .
Jordheim LP, Peters GJ. Recent updates on purine and pyrimidine metabolism in physiological and pathological settings. Nucl Nucl Nucl Acids. 2020;39:1273–80.
doi: 10.1080/15257770.2020.1730891
Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? Am J Med. 2005;118:816–26.
pubmed: 16084170
doi: 10.1016/j.amjmed.2005.03.043
De Lucchi L, Nardin C, Sponchiado A, Raggi D, Faggin E, Martini E, et al. Serum uric acid levels and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2021;19:194–201.
pubmed: 33078502
doi: 10.1111/jth.15139
Weng H, Li H, Zhang Z, Zhang Y, Xi L, Zhang D, et al. Association between uric acid and risk of venous thromboembolism in East Asian populations: a cohort and Mendelian randomization study. Lancet Reg Health—West Pac [Internet]. 2023 [cited 2023 Sep 20];39. Available from: https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(23)00166-9/fulltext .
Liu X, Zheng Y, Guasch-Ferré M, Ruiz-Canela M, Toledo E, Clish C, et al. High plasma glutamate and low glutamine-to-glutamate ratio are associated with type 2 diabetes: case-cohort study within the PREDIMED trial. Nutr Metab Cardiovasc Dis NMCD. 2019;29:1040–9.
pubmed: 31377179
doi: 10.1016/j.numecd.2019.06.005
Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvención con DIeta MEDiterránea (PREDIMED) Trial [Internet]. [cited 2023 Sep 21]. Available from: https://doi.org/10.1161/JAHA.116.003755 .
Za’abi MA, Ali BH, Ali I. Advances in the methodologies for the analysis of acute kidney injury biomarkers. Recent Pat Biomark. 2023;5:81–92.
Jayaraj RL, Narchi H, Subramanian R, Yuvaraju P. Development and validation of LC–MS/MS method for quantification of ATP, ADP and AMP in dried blood spot, liver and brain of neonate mice pups. Results Chem. 2021;3:100172.
doi: 10.1016/j.rechem.2021.100172
Cortese M, Delporte C, Dufour D, Noyon C, Chaumont M, De Becker B, et al. Validation of a LC/MSMS method for simultaneous quantification of 9 nucleotides in biological matrices. Talanta. 2019;193:206–14.
pubmed: 30368292
doi: 10.1016/j.talanta.2018.10.003
Hakuna L, Doughan B, Escobedo JO, Strongin RM. A simple assay for glutathione in whole blood. Analyst. 2015;140:3339–42.
pubmed: 25913023
pmcid: 4449837
doi: 10.1039/C5AN00345H